| Document |
Document Title |
|
WO/2023/227666A1 |
The present disclosure relates to a method of treating an acute inflammatory condition in a subject comprising administering to the subject a therapeutically effective amount of a pyrimidinone compound.
|
|
WO/2023/229282A1 |
The present invention relates to a composition for preventing, treating, or improving metabolic diseases, comprising a Lactobacillus kunkeei NCHBL-003 strain or a culture medium thereof, wherein the composition not only inhibits adipocyt...
|
|
WO/2023/226904A1 |
Provided are an intestinal tract targeted pentacyclic triterpene TGR5 receptor agonist, a preparation method therefor and a use thereof. The structure is as shown in formula (I). The compound can be used for preparing drugs for treating ...
|
|
WO/2023/230468A1 |
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
|
|
WO/2023/227492A1 |
The invention relates to novel aqueous pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more solubilizing agents as well as corresponding processes of manufacturing such aqueous pharmaceutical compositions ...
|
|
WO/2023/228156A1 |
Triple agonist peptides having activities at each of GLP-1, Glucagon and GIP receptors are provided. Triple agonist analogs having one or more biotin moieties and/or fatty acid moieties conjugated thereto for improved bioavailability and...
|
|
WO/2022/226191A9 |
The disclosure provides method of enhancing neuronal, vascular cell, and macrophage proteostasis, in a subject by administering a CMA activator to the subject. Enhancing proteostasis is a method of preventing or slowing advancement of an...
|
|
WO/2023/226789A1 |
Provided are a functionalized targeting formulation, a method for preparing same, and a use thereof. The functionalized targeting formulation comprises an amphiphilic polymer and a biological agent. The amphiphilic polymer comprises a mo...
|
|
WO/2023/229263A1 |
The present invention relates to a composition for preventing, treating, or improving metabolic diseases comprising Lactobacillus plantarum NCHBL-004 strain or a culture medium thereof, and the composition not only inhibits adipocyte dif...
|
|
WO/2023/230213A1 |
The present application relates to keratin protein extracts, compositions, methods and uses thereof. In some embodiments, the keratin protein extract is a beta-keratin extract. In some embodiments, the compositions are beta-keratin compo...
|
|
WO/2023/225741A1 |
Described herein are Mincle-binding DNA aptamers and uses thereof.
|
|
WO/2023/227184A2 |
|
|
WO/2023/223237A1 |
The object of the present invention is to use the strain of bacteria named Lacticaseibacillus paracasei DG® CNCM I‐1572 DSM 34154 for use in a method of treating dysbiosis, particularly in patients with IBS (Irritable Bowel Syndrome),...
|
|
WO/2023/224128A1 |
The present invention relates to a pharmaceutical composition for treating or preventing fibrosis, the pharmaceutical composition containing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/223344A1 |
The present invention discloses compositions comprising methylxanthines in combination with disaccharides derived from enzymatic conversion of sucrose. More particularly, the present invention discloses compositions comprising methylxant...
|
|
WO/2023/223223A1 |
The present invention relates to a pharmaceutical composition for use in preventing and/or reducing hepatotoxicity induced by acetaminophen. Said pharmaceutical composition comprises a combination of acetaminophen and nefopam, as nefopam...
|
|
WO/2023/225445A1 |
The present disclosure relates to compositions and methods for increasing the level of Klotho in a cell or in a subject and in particular to compositions and methods for treating diseases or conditions associated with Klotho. The methods...
|
|
WO/2023/224554A1 |
The present invention relates to an expression cassette comprising a Type III interferon gene, and a nitric oxide-inducible promoter operably linked to the Type III interferon gene. In an embodiment, the Type III interferon gene encodes ...
|
|
WO/2023/221361A1 |
The present invention provides use of a small-molecule inhibitor BAY87-2243 in preparing a drug for treating hepatitis B virus infection. According to the present invention, by using different hepatoma cell lines stably producing hepatit...
|
|
WO/2023/223309A1 |
The present invention provides novel stimulator of IFN genes inhibitors and methods of using same, such as for treating inflammatory diseases.
|
|
WO/2023/222137A1 |
Provided are a novel tetrahydroisoquinoline compound, a preparation method therefor, a pharmaceutical composition containing said compound, and a use thereof. Specifically, provided are a nitrogen-containing heterocyclic compound as repr...
|
|
WO/2023/225650A1 |
Provided herein are functional moieties including at least one β-amino-acid within an amino-acid cluster for conjugation with one or more ligands. The functional moieties are useful for linking a macromolecule with the one or more funct...
|
|
WO/2023/223235A1 |
The present invention relates to a method for producing a liposomal preparation by emulsification, the preparation containing liposomes with encapsulated hormones, comprising: a first emulsification step of emulsifying a first compositio...
|
|
WO/2023/222849A1 |
The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tre...
|
|
WO/2023/224465A1 |
The invention relates to an insect composition for use as a medicament, and for use in a method for the restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food...
|
|
WO/2023/221419A1 |
The present invention relates to a crystal form of Vonoprazan pyroglutamate and a preparation method therefor. The crystal form of Vonoprazan pyroglutamate obtained in the present invention not only has good solubility, but also has exce...
|
|
WO/2023/222865A1 |
The present invention relates to an azolo compound of Formula (I) for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFB-activated fibroblasts and reverses collagen production to the n...
|
|
WO/2023/222124A1 |
Disclosed in the present invention are a 5,6-dihydro-1,2,4-triazine compound and the pharmaceutical use thereof as a GLP-1 receptor agonist. A structure of the 5,6-dihydro-1,2,4-triazine compound is represented by formula (I), and in the...
|
|
WO/2023/224135A1 |
The present invention relates to superoxide dismutase, and uses thereof for preventing or treating mucositis. The superoxide dismutase according to the present invention can be effectively used for treating or improving the inhibition of...
|
|
WO/2023/221987A1 |
Provided are a composition for alleviating oral damage, use thereof and a method for preparing the same. The composition comprises mitochondria and a biologically acceptable carrier, and may also comprise extracellular vesica or extracel...
|
|
WO/2023/223257A1 |
The specification relates to 2-(difluoromethoxy)-5-(5-((5-fluoroadamantan-2-yl)(methyl)am
ino)- 1,3,4-oxadiazol-2-yl)phenol or 5-(3-(((1-cyclohexyl-1H-tetrazol-5-yl)methyl)(methyl)amino)-
1,2,4- oxadiazol-5-yl)-2-fluorophenol, and to pha...
|
|
WO/2023/222316A1 |
The invention relates to a rinse solution for a photodynamic disinfection, in particular an oral disinfection, containing, in each case based on the total rinse solution, at least one photosensitizer from the group consisting of riboflav...
|
|
WO/2023/225282A1 |
Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or ki...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/221533A1 |
The present invention belongs to the technical field of medicines and healthcare foods. Particularly, the present invention provides a micromolecule composition for negatively regulating the Nrf2 signaling pathway, comprising licochalcon...
|
|
WO/2020/117508A9 |
Embodiments of the invention include a system having a plant stem cell product and a delivery device configured to deliver an effective amount of the plant stem cell product to the oral cavity or nasopharynx. In some embodiments, the del...
|
|
WO/2023/224464A1 |
The invention is in the field of health promoting or health restoring capabilities of insect fat. The invention relates to an insect composition for use as a medicament, and for use in a method for the prophylaxis or treatment of (intest...
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/224585A1 |
In particular, the invention relates to a pharmaceutical agent for the prevention and/or elimination of the adverse effects of the rotavirus NSP4 viral protene in cells and/or organisms using the Lactobacillus plantarum bacteriocin PlnA.
|
|
WO/2023/218305A1 |
The invention provides a method for inactivating SARS-CoV-2 in a sample comprising at least one recombinant protein, wherein the method comprises treating the sample at a pH of between 2.6 and 3.4.
|
|
WO/2023/217020A1 |
Disclosed in the present invention are an immunoglobulin κ-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the Vκ4-1-IgLC polypeptide is as shown in SEQ ID NO.1, and the...
|
|
WO/2023/220549A1 |
The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
|
|
WO/2023/217179A1 |
Provided is use of mannose in inhibiting pyroptosis or relieving toxic and side effects of a chemotherapy drug, which relates to the field of medical science and technologies. Mannose inhibits pyroptosis induced by a chemotherapy drug, s...
|
|
WO/2023/217132A1 |
A preparation method for and the use of gallbladder precursor-like cells. The preparation method for the gallbladder precursor-like cells comprises the following steps: taking gallbladder tissue, and subjecting the gallbladder tissue to ...
|
|
WO/2023/217743A1 |
It is disclosed BTN3A inhibitory antibodies for use in treating gastro-intestinal inflammatory disorders, such as inflammatory bowel disease. The disclosure more specifically relates to specific anti-BTN3A antibodies that specifically bi...
|
|
WO/2023/219175A1 |
The present disclosure relates to: a method and a composition both for treating IBD using digestive tract contents or an excrement each modified with an IgA antibody, and a method for producing the composition; a method for obtaining an ...
|
|
WO/2023/216280A1 |
Provided is use of the ferroptosis inhibitor in the preparation of a drug for treating gastritis. The ferroptosis inhibitor uses Ferrostatin-1, or a derivative, an isomer or a pharmaceutically acceptable salt thereof as an active ingredi...
|
|
WO/2023/218480A1 |
The present invention relates to oral liquid formulation of famotidine or pharmaceutically acceptable salt thereof. The present invention also relates to the process for the preparation of said liquid formulation. The liquid formulation ...
|
|
WO/2023/217981A1 |
The invention concerns a carbon monoxide-releasing molecule (CORM) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject. More particularly, the invention concerns a carbon monoxide-rel...
|
|
WO/2023/219499A1 |
This invention pertains in general to therapy using pre-treated T cells and/or vesicles secreted by these T cells. In particular there is provided for the use of such pre-treated T cells and/or vesicles secreted by these T cells as a med...
|
